This Article Full Text Full Text (PDF) All Versions of this Article: 1055-9965.EPI-07-0726v1 17/5/1028    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kumar, A. S. Articles by Esserman, L. J. Search for Related Content PubMed PubMed Citation Articles by Kumar, A. S. Articles by Esserman, L. J. Related Collections Epidemiology Epidemiology: Classical Epidemiology

Estrogen Receptor–Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users

¹ Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California; ² Department of Surgery, University of California-San Francisco; ³ Department of Medicine, Division of Hematology and Oncology, and ⁴ Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California; and ⁵ Buck Institute for Age Research, Novato, California

Requests for reprints: Laura J. Esserman, Carol Franc Buck Breast Care Center, 2nd Floor, 1600 Divisadero Street, San Francisco, CA 94115. Phone: 415-885-7691; Fax: 415-353-9571. E-mail: laura.esserman{at}ucsfmedctr.org

Background: Preclinical studies have shown the anticancer potential of HMG-CoA reductase enzyme inhibitors (statins), whereas epidemiologic studies remain controversial. Because lipophilic statins show preclinical anticancer activity against hormone receptor [estrogen receptor (ER)/progesterone receptor (PR)]–negative breast cancer models, we explored the hormone receptor phenotype of breast cancers that arise in statin users.

Methods: We did a retrospective cohort analysis via electronic pharmacy records from the Kaiser Permanente Northern California Cancer Registry on 2,141 female patients listed in 2003 as incident cases of breast malignancy. Measures included tumor grade, stage, and receptor phenotype in statin users versus nonusers and controlled for hormone replacement therapy and race.

Results: 387 of the 2,141 breast cancer patients used lipophilic statins [lovastatin (85%), simvastatin, and atorvastatin]. Fifty-one women developed ER/PR-negative tumors. The age-adjusted odds ratio (OR) of developing an ER/PR negative tumor was 0.63 (95% confidence interval, 0.43-0.92; P = 0.02) for statin use 1 year before breast cancer diagnosis compared with statin use <1 year (including nonuse). Breast cancers in patients with 1 year of statin use were more likely to be low grade (OR, 1.44) and less invasive stage (OR, 1.42).

Conclusions: Breast cancer patients with exposure to statins have proportionately fewer ER/PR-negative tumors that are of lower grade and stage. Although our data set cannot address whether statins affect the incidence of breast cancer, we show that statin use may influence the phenotype of tumors. This suggests a new potential strategy for breast cancer prevention, that of combining statins with agents that prevent ER-positive cancer (tamoxifen, aromatase inhibitors). (Cancer Epidemiol Biomarkers Prev 2008;17(5):1028–33)

This article has been cited by other articles:

				N K Wenger, V Bittner, D M Herrington, S J Lewis, and F K Welty The TNT study, women and cancer Heart, February 1, 2009; 95(3): 250 - 250. [Full Text] [PDF]